DPP4 and diabetes mellitus: Saxagliptin, a competitive inhibitor of dipeptidyl peptidase-4 (DPP-4), stands as a cornerstone in diabetes management, enhancing insulin production by elevating glucagon-like peptide-1 (GLP-1) levels and promoting the conversion of GLP-1 into its inactive form [5].